Ivermectin Versus Albendazole for Chronic Strongyloidiasis

Mahidol University90 enrolled

Overview

A prospective controlled trial to compare the efficacy and safety of 7-day albendazole, single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Strongyloidiasis

Interventions

IvermectinDRUG

single dose of 200 mcg/kg

ivermectinDRUG

two single dose of 200mcg/kg in 2 weeks

AlbendazoleDRUG

Albendazole 7 days

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with positive strongyloides larva in the stool Exclusion Criteria: * Pregnancy * Lactating women * Known allergy to any study drug

Locations (1)

Siriraj Hospital

Bangkoknoi, Bangkok, Thailand

Outcomes

Primary Outcomes

cure rate

Time frame: 1 year

Secondary Outcomes

safety

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.